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Abstract 
Nobiletin, a citrus flavonoid, shows strong cytotoxic effect in several 
cancer cell lines. The aim of this research was to investigate cytotoxic 
activities of nobiletin alone and in combination with doxorubicin. Cell 
viability assay of nobiletin, doxorubicin, and combination treatments 
were carried out by using MTT assay. Apoptosis assay was done using 
double staining method using Ethidium Bromide-Acridine Orange. Cell 
cycle distribution was determined by flowcytometry FACS-Calibur and 
data was analyzed by using ModFit LT 3.0 program. Nobiletin (5, 10 and 
15 µM) increased cytotoxic effect of doxorubicin compared with 
doxorubicin alone in MCF-7 cells but not in T47D cells. The strongest 
cytotoxic activity was showed by the combination of 200 nM 
doxorubicin and 15 µM nobiletin in MCF-7 cells. Single treatment of 
doxorubicin 200 nM, nobiletin 15 µM and their combination induced 
G2/M accumulation in MCF-7 cells. Combination of 15 µM and 
nobiletin 200 nM doxorubicin showed strong synergism on apoptosis 
induction of MCF-7 cells. Single treatment of nobiletin 15 µM and 
doxorubicin 7.5 nM induced T47D cell accumulation in G1 phase and 
G2/M phase respectively, while their combination induced accumulation 
of T47D cells in G2/M phase. Nobiletin is potentially to be developed as 
co-chemotherapeutic agent for breast cancer, while molecular mechanism 
need to be explored.  
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Introduction 
The incidency of breast cancer is increasing in 
several decades and become major as death 
caused cancer in women [1]. Several methods for 
breast cancer therapy such as surgery, 
chemotherapy, hormonal therapy and 
radiotherapy had been established. Doxorubicin 
is the common chemotherapeutic agent used in 
breast cancer therapy, but its effectivity is limited 
because of drug resistance problem and its 
toxicity in normal cells. To improve the 
antitumor efficacy of chemotherapy, a 
combination with chemopreventive agent (co- 
 
 
chemotherapy) would be interesting to evaluate 
[2] 
Nobiletin (5,6,7,8,3',4'-hexamethoxy flavone) has 
been proved to inhibit some kinds of tumor cells 
proliferation. Nobiletin blocked carcinogenesis 
on mice induced DMBA skin [3]. Nobiletin 
inhibited cell proliferation, and also induced 
apoptosis on HepG2 cells [4].  Nobiletin showed 
cytotoxic effect, induced apoptosis and 
modulated cell cycle on TMK-1, MKN-45, 
MKN-74 and KATO-III cells [5]. Nobiletin 
induced G1 arrest on MDA-MB-435, MCF-7 and 
HT-29 [6], and the newest study mentioned that 
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nobiletin has chemopreventive effects against 
colon carcinogenesis [7]. However, knowledge of 
the effect of nobiletin in combination with 
doxorubicin on breast cancer cells is unknown. 
Therefore, the present study was carried out to 
address the issue if nobiletin has potency as co-
chemotherapeutic agent of doxorubicin. 
 
Those researches showed the potency of nobiletin 
as chemopreventive agent and became a basic for 
the development of nobiletin as co-
chemotherapeutic agent to increase the cytotoxic 
activity and reduce the side effects of 
doxorubicin. Therefore, the purpose of this 
research is to examine the effect of nobiletin 
alone and combination with doxorubicin on 
cytotoxicity, cell cycle and apoptosis induction of 
MCF-7 and T47D breast cancer cells. 
 
Materials and Methods 
Materials  
Nobiletin was obtained from Sigma Aldrich 
Chemie GmBH, Steinheim, Germany (Cat No. 
N1538) while doxorubicin was obtained from 
Ebewe. A DMSO (Sigma Aldrich Chemie 
GmBH, Steinheim, Germany) solution of 
nobiletin was used for in vitro experiment by 
diluting appropriate consentration.  
 
Doxorubicin Ebewe ((vial 10mg/5ml) obtained 
from P.T. Ferron Par Pharmaceutical (Cikarang, 
Indonesia))  was diluted directly in culture 
medium. The final DMSO concentration was set 
at less then 0.1 %.  
 
Cell Lines 
MCF-7 and T47D cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing Fetal Bovine Serum (FBS) 10% (v/v) 
(FBS qualified, Gibco, InvitrogenTM USA) and 
penicillin-streptomycin 1 % (v/v) (Gibco, 
Invitrogen Corporation, Grand Island, NY, 
14072, USA). Those cell lines were kindly 
provided by Prof. Tatsuo Takeya (Nara Institute 
of Science and Technology, Nara, Japan).  
 
 
Cytotoxic Assay (MTT Method) 
The method was modified from Mosmann 
(1983). Cells (5x103 cells/well) were transfered to 
96-well plate (Iwaki) and incubated for 24 hours 
(70-80% confluent). Cultures were maintained in 
a humidified incubator at 37 oC in an atmosphere 
of 5% CO2 and 95% air. Cells were treated by 
nobiletin, doxorubicin, and their combination, 
and incubated for 24 hours. At the end of the 
incubation, 0,5 mg/ml MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide] (Sigma, Sigma-Aldrich Corp, St. Louis, 
MO, USA) were added to each wells and the cells 
were incubated for 4 hours in 37°C. Viable cells 
reacts with MTT to form purple formazan crystal. 
After 4 hours, stopper sodium dodesil sulphate 
10% in 0,1 N HCl solution were added to 
dissolve formazan crystal. Cells were incubated 
over night and protected from light. Cells were 
shaken for 10 minutes before read by ELISA 
reader at λ 595 nm. The absorbance of each well 
converted to percentage of viable cells : 
 
 
 
Apoptotic Assay (Double Staining Method) 
Cells (5x104 cells/well) were transfered to 
coverslips (Nunc) in 24-well plate (Iwaki) and 
incubated for 24 hours (50-60% confluent). Cells 
were treated by nobiletin, doxorubicin, and their 
combination, and then incubated for 15 hours. At 
the end of the incubation, coverslips containing 
cells were moved to object glass. Mixture 
solution of etidium bromide-acridine orange 
(Sigma, Sigma-Aldrich Corp, St. Louis, MO, 
USA) were added to the cells to form 
fluorescence cells. The fluorescence cells were 
examined by fluorescence microscope (Zeiss 
MC80) immediately. Green fluorescence cells 
showed viable cells, while red fluorescence cells 
showed dead cells. 
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Figure 1. Chemical structure of nobiletin. 
 
Cell cycle Analysis 
Cells (5x105 cells/well) were transferred into 6-
well plate (Iwaki) and incubated until the cells 
return to normal condition. Cells were treated by 
nobiletin, doxorubicin, and their combination, 
and incubated for 24 hours. Cultures were 
maintained in a humidified incubator at 37 oC in 
an atmosphere of 5% CO2 and 95% air. At the 
end of the incubation, the media containing free 
cells suspension were taken and transferred into 
1.5 ml eppendorfs, then it were centrifugated 
(2000 rpm, 3 minutes) and the supernatant were 
removed. The cells in 6-well plate were added by 
PBS, and the PBS was transferred into previous 
eppendorfs. The eppendorfs were centrifugated 
and the supernatant were removed again. This 
steps were repeated before the cells harvested by 
trypsin-EDTA 0.25% (Gibco, Invitrogen, 
Canada).  
 
Harvested cells were transferred into the 
eppendorfs and centrifugated (2000 rpm, 30 
seconds). The remaining cells in the 6-well plate 
were rinsed with PBS and transferred into the 
eppendorfs. The eppendorfs were centrifugated 
and the supernatant were removed. Pellet cells in 
eppendorfs washed by cold PBS and added by 
propidium iodide (PI) reagents. The eppendorfs 
were wrapped in aluminum foil and incubated in 
37ºC for 10 minutes. After 10 minutes, cell 
suspension was homogenated and transferred into 
the flowcyto-tube to be analyzed by FACS 
flowcytometer. 
 
 
Statistical Analysis 
Statictical analysis was performed using 
Student’s t-test and results considered significant 
at the p<0.05 level. 
 
Result and Discussion 
Cytotoxic Assay 
In this study we explored the effect of nobiletin 
alone and combination with doxorubicin on 
cytotoxicity, cell cycle and apoptosis induction of 
MCF-7 and T47D breast cancer cells. Nobiletin 
have been proved to have cytotoxic and 
antiproliferative effect against several cancer cell 
lines such as HepG2, TMK-1, MKN-45, MKN-
74 and KATO-III cells. Our study showed that 
single treatment of nobiletin did not show 
cytotoxic effect on MCF-7 and T47D cells 
because nobiletin is slightly soluble in culture 
medium. The maximum soluble concentration of 
nobiletin is 15 µM. Our previous study showed 
that doxorubicin showed strong cytotoxic effect 
on MCF-7 and T47D breast cancer cell lines with 
IC50 value 400 and 15 nM, respectively 
(Hermawan et al., 2010; Junedi et al., 2010). This 
is due to the characteristic of MCF-7 which is 
resistant to doxorubicin by overexpressing anti-
apoptotic protein Bcl-2 and P-glycoprotein efflux 
pump [8]. While T47D cells resistance to 
apoptosis because of mutation of p53 gene. To 
increase the sensitivity of MCF-7 and T47D cells 
towards doxorubicin, we combined doxorubicin 
with nobiletin. 
 
Combination of doxorubicin with nobiletin 5, 10, 
and 15 μM showed higher inhibition of 
proliferation than single treatment of doxorubicin 
in MCF-7 breast cancer cell lines (Figure 2), but 
not increase doxorubicin cytotoxicity on T47D 
cells (Figure 3). This result suggested that this 
combination give synergistic effect on MCF-7 
cells. This synergistic effect is occured due to 
apoptotic induction and cell cycle modulation. 
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Figure 2.  The effect of nobiletin and doxorubicin to the viability of MCF-7 breast cancer cells. 
 
The combination effect of nobiletin and doxorubicin to the proliferation of MCF-7 (A), control (B), doxorubicin 200 nM 
(C), nobiletin 15 µM (D), combination doxorubicin 200 nM-nobiletin 15 µM (E). The assay performed by incubating 
5x103 cells/well with nobiletin (5-15 µM) and doxorubicin (200  nM) on MCF-7 for 24 hours. After 24 hours, cells were 
added by MTT reagent to calculate the absorbance which represent viable cells. Cell viability profile was shown from 
average ± standard of error (SE) of 3 experiment. Death cell was pointed by red arrow. Cell morphology was examined 
by using inverted microscope with magnification 400 x. Nobiletin increased cytotoxicity of doxorubicin 200 nM. 
 
 
 
 
Figure 3. The effect of nobiletin and doxorubicin to the viability of T47D breast cancer cells. 
 
The combination effect of nobiletin and doxorubicin to the proliferation of T47D (A), control (B), doxorubicin 7.5 nM 
(C), nobiletin 15 µM (D), combination doxorubicin 7.5 nM-nobiletin 15 µM (E). The assay performed by incubating 
5x103 cells/well with nobiletin (5-15 µM) and doxorubicin (7.5 nM) on T47D for 24 hours. After 24 hours, cells were 
added by MTT reagent to calculate the absorbance which represent viable cells. Cell viability profile was shown from 
average ± standard of error (SE) of 3 experiment. Death cell was pointed by red arrow. Cell morphology was examined 
by using inverted microscope with magnification 400 x. Nobiletin did not increase cytotoxicity of doxorubicin 7.5 nM. 
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Apoptosis Assay 
We next investigated wheter the nobiletin 
increased apoptosis induction of doxorubicin in 
MCF-7 and T47D cells. The results from 
cytotoxic assay of doxorubicin and nobiletin were 
parallel with apoptotic assay using double 
staining method. All cells in control cell showed 
green fluorescence means there was no death cell. 
Orange fluorescence cells represent apoptotic 
cells that loss cell membrane permeability and 
form apoptotic bodies. The nuclear of several 
cells were fragmented and formed apoptotic 
bodies. On MCF-7 (Figure 4) cells single 
treatment of doxorubicin 200 nM induced 
apoptosis, but there were several viable cells, 
while single treatment of nobiletin 15 µM did not 
show apoptosis induction. Combination of 
doxorubicin 200 nM and nobiletin 15 µM 
increased the incidence of apoptosis, compared 
with single treatment of doxorubicin 200 nM on 
MCF-7 cells.  
 
On T47D cells (Figure 5) cells single treatment of 
doxorubicin 7.5 nM induced apoptosis in almost 
of cells, while single treatment of nobiletin 15 
µM did not show apoptosis induction. 
Combination of doxorubicin 7.5 nM and 
nobiletin 15 µM did not increase the incidence of 
apoptosis, compared with single treatment of 
doxorubicin on T47D cells. Probably the 
apoptosis incidence in combinational treatment is 
dominantly because of doxorubicin 7.5 nM.
 
 
Figure 4. Apoptotic effect of doxorubicin, nobiletin and their combination on MCF-7 cells. 
 
MCF-7 cell were treated by doxorubicin, nobiletin and their combination for 15 hours and stained by etidium bromide-
acridine orange. (A) Cell control, (B) Doxorubicin 200 nM, (C) Nobiletin 15 μM, (D) Combination of nobiletin 15 μM and 
doxorubicin 200 nM. Viable cells give green fluorescence, apoptotic cells give orange fluorescence (poinetd by red 
arrow). Examination of apoptosis was done by using fluorescent microscope with magnification 400 x. Nobiletin 
increased apoptosis induction of doxorubicin on MCF-7 cells. 
 
 
Figure 5. Apoptotic effect of doxorubicin, nobiletin and their combination on T47D cells. 
 
T47D cell were treated by doxorubicin, nobiletin and their combination for 15 hours and stained by etidium bromide-
acridine orange. (A) Cell control, (B) Doxorubicin 7.5 nM, (C) Nobiletin 15 μM, (D) Combination of nobiletin 15 μM and 
doxorubicin 7.5 nM. Viable cells give green fluorescence, apoptotic cells give orange fluorescence (poinetd by red arrow). 
Examination of apoptosis was done by using fluorescent microscope with magnification 400 x. Nobiletin did not increase 
apoptosis induction of doxorubicin on T47D cells.  
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Figure 7.  T47D cell cycle analysis after treatment of doxorubicin, nobiletin and their combination. 
 
T47D cell were treated by doxorubicin, nobiletin and their combination for 24 hours and stained by PI reagent before 
analyzed by flowcytometer. (A) Cell control, (B) doxorubicin 7.5 nM, (C) nobiletin 15 μM, (D) Combination of 
doxorubicin 7.5 nM-nobiletin 15 μM. 
 
Cell Cycle Analysis 
In the next series of experiments, we explored the 
possibility of cell cycle perturbation by nobiletin, 
doxorubicin and their combination in MCF-7 and 
T47D cells. Synergistic effect of combination 
between nobiletin and doxorubicin could be 
occured via MCF-7 cell cycle modulation (Table 
1 and Figure 6). Cell cycle analysis of MCF-7 
breast cancer cell lines showed that single 
treatment of Doxorubicin 200 nM induced G2/M 
arrest. Single treatment of nobiletin 15 µM 
induced G1 arrest, and combination of 
doxorubicin 200 nM-nobiletin 15 µM induced 
G2/M arrest on MCF-7 cells. T47D cell cycle 
profile (Table 2 and Figure 7) after treatment of 
doxorubicin 7.5 nM induced G2/M arrest. Single 
treatment of nobiletin 15 µM induced S arrest, 
and combination of doxorubicin 7.5 nM-nobiletin 
15 µM induced G2/M arrest on T47D cells. 
 
 
Table 1. MCF-7 Cell distribution after treatment of doxorubicin, nobiletin and their combination for 24 hours. 
Treatment Concentration G1 (%) S (%) G2/M (%) 
control - 47,94  40,60        11,47  
doxorubicin          200 nM  34,82        45,56 19,62  
nobiletin 15 μM  47,73   36,63  15,63 
doxorubicin and nobiletin 200 nM -15 μM 35,92         29,48 34,60  
 
 
Table 2. T47D Cell distribution after treatment of doxorubicin, nobiletin and their combination for 24 hours 
Treatment Concentration G1 (%) S (%) G2/M (%) 
control - 38,73  43,87  17,40 
doxorubicin          7.5 nM  22,53        16,89 60,58 
nobiletin 15 μM  34,07   46,96  18,97 
doxorubicin and nobiletin 7.5 nM-15 μM 22,15         29,50 48,35 
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Figure 6.  MCF-7 cell cycle analysis after treatment of doxorubicin, nobiletin and their combination. 
 
MCF-7 cell were treated by doxorubicin, nobiletin and their combination for 24 hours and stained by PI reagent before 
analyzed by flowcytometer. (A) Cell control, (B) doxorubicin 200 nM, (C) nobiletin 15 μM, (D) Combination of 
doxorubicin 200 nM-nobiletin 15 μM. 
 
MCF-7 cells showed lower sensitivity to 
doxorubicin than T47D cells [9]. Over expression 
of Bcl-2 and P-glyco Protein (PgP) in MCF-7 
cells caused cells resistance to apoptosis triggered 
by doxorubicin. Over expression of Bcl-2 caused 
cells evading the apoptosis mechanism [10] while 
PgP transport the drug outside the cells so that 
concentration of chemotherapeutic agent inside 
the cells will be low and failed to kill the cancer 
cells. T47D is one one cancer cell model with 
mutant p53, and doxorubicin treatment in 
increasing dose  in this cells induced drug 
resistance phemonema via upregulation of Akt 
and PgP [11,12]. Drug resistant in cancer cells 
could be occured by cell cycle arrest that will 
repair the DNA damage caused by 
chemotherapeutic agent, so combination of 
chemotherapeutics with an agent which modulate 
cancer cell cycle is interesting to be studied. 
 
Single treatment of nobiletin did not show 
cytotoxic effect, but the combination with 
doxorubicin increased cytotoxicity of 
doxorubicin in MCF-7 cells. Single treatment of 
nobiletin did not induced apoptosis, but the 
combination with doxorubicin increased 
apoptosis induction of doxorubicin in MCF-7 
cells. The combination also increased G2/M 
arrest of MCF-7 cells. The mechanism of 
increasing of doxorubicin cytotoxicity by 
nobiletin probably because of up-regulation of 
p53 and its related pathway. Doxorubicin induced 
DNA damage and trigger the apoptosis pathway 
or DNA repair depend on the degree of DNA 
damage [13]. In the cells with wild type p53 e.g. 
MCF-7 cells, upregulation of p53 could increase 
apoptosis induction or G2/M arrest. [14] 
mentioned nobiletin induced apoptosis via p53 
up-regulation and those phenomena was 
correlated with G2/M arrest in A549 lung cancer 
cells. Our reults is similar to the previous study, 
but the mechanism need to be explored more 
details in MCF-7 cells. 
 
In T47D cells, single treatment of nobiletin and 
its combination with doxorubicin did not increase 
cytotoxicity and apoptosis induction of 
doxorubicin. While single treatment of nobiletin 
increased S arrest, and its combination with 
doxorubicin decreased G2/M arrest of 
doxorubicin single treatment, so probably this 
mechanism triggered the cell resistance to 
doxorubicin. Apoptosis pathway in T47D cells 
did not occured via p53 because of mutant p53 in 
this cells. Probably nobiletin increased p53 
expression in MCF-7 cells, but did not in T47D 
cells so that nobiletin did not increase 
cytotoxicity of doxorubicin, but the mechanism 
need to be explored more details.  
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This result showed the potency of nobiletin to be 
delevoped as co-chemotherapeutic agent for 
doxorubicin by inducing apoptosis and cell cycle 
arrest. The use of doxorubicin together with 
nobiletin is expected to increase the activity and 
reduce the side effects of doxorubicin. However, 
the molecular mechanism of apoptotic induction 
and cell cycle arrest by this combination need to 
be explored further.  
 
Conclusion 
This research showed that combination of 
nobiletin and doxorubicin synergically increase 
the effect of doxorubicin through apoptotic 
induction and cell cycle modulation. Based on 
this result, nobiletin is potential to be delevoped 
as co-chemotherapeutic agent for doxorubicin in 
breast cancer therapy.  
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